The potential of pirtobrutinib in multiple B-cell malignancies

Bruton’s tyrosine kinase (BTK) is a critical downstream signaling element from the B-cell receptor (BCR) that has been effectively inhibited in B-cell cancers by irreversible, covalent inhibitors including ibrutinib and acalabrutinib. All FDA-approved covalent BTK inhibitors rely on binding to the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Jeffrey L., Mato, Anthony R., Pena, Camila, Roeker, Lindsey E., Coombs, Catherine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210100/
https://www.ncbi.nlm.nih.gov/pubmed/35747462
http://dx.doi.org/10.1177/20406207221101697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210100/
https://www.ncbi.nlm.nih.gov/pubmed/35747462
http://dx.doi.org/10.1177/20406207221101697

Ejemplares similares